Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	22024
Country	United Kingdom

Received	2015-08-08 13:34
Peer-Review Started	2015-08-11 16:15
To Make the First Decision	2015-09-16 13:59
Return for Revision	2015-09-22 10:12
Revised	2015-10-12 18:08
Second Decision	2015-11-30 09:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-12-11 16:44
Articles in Press	2015-12-11 16:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-29 16:06
Publish the Manuscript Online	2016-02-02 18:35

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
Manuscript Source	Invited Manuscript
All Author List	Kiruthikah Thillai, Paul Ross and Debashis Sarker
Funding Agency and Grant Number	Funding Agency Grant Number Department of Health via the National Institute for Health Research Biomedical Research Centre award to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust
Corresponding Author	Dr. Debashis Sarker, Division of Cancer Studies, King’s College London, Guy’s Hospital Campus, Great Maze Pond, London Bridge, London SE1 9RT, United Kingdom. debashis.sarker@kcl.ac.uk
Key Words	Hepatocellular carcinoma; Molecular targets; Genomics; Sorafenib; Tyrosine kinase inhibitors
Core Tip	This review discusses the current drug therapy landscape for advanced hepatocellular carcinoma, in particular the reasons for failure of several clinical trials of molecularly targeted therapy and future directions of research to address these problems.
Publish Date	2016-02-02 18:35
Citation	Thillai K, Ross P, Sarker D. Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? World J Gastrointest Oncol 2016; 8(2): 173-185
URL	http://www.wjgnet.com/1948-5204/full/v8/i2/173.htm
DOI	http://dx.doi.org/10.4251/wjgo.v8.i2.173

Full Article (PDF)	WJGO-8-173.pdf
Full Article (Word)	WJGO-8-173.doc
Manuscript File	22024-Review.docx
Answering Reviewers	22024-Answering reviewers.pdf
Audio Core Tip	22024-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	22024-Conflict-of-interest statement.pdf
Copyright License Agreement	22024-Copyright assignment.pdf
Peer-review Report	22024-Peer-review(s).pdf
Scientific Misconduct Check	22024-Scientific misconduct check.pdf
Scientific Editor Work List	22024-Scientific editor work list.pdf